Tart cherry juice for sleep: melatonin content and trial effects

Montmorency tart cherries (Prunus cerasus) appear regularly on wellness lists as a "natural source of melatonin." The claim is technically true and pharmacologically smaller than the marketing implies. A representative 240 mL serving of unconcentrated tart cherry juice contains roughly 0.13 mg melatonin per kg of dry weight in measured analyses — translating to single-digit micrograms per glass. The interesting part is whether that, combined with tryptophan and anti-inflammatory anthocyanins, produces measurable sleep effects in adults.

What the small RCTs found

The 2010 crossover RCT by Pigeon and colleagues in 15 older adults with insomnia found that 240 mL twice daily of tart cherry juice for 2 weeks modestly reduced insomnia severity index scores and improved subjective sleep quality versus placebo (PMID: 20438325).¹ A larger 2018 RCT in 8 older adults with insomnia measured polysomnographic outcomes and reported a 1-hour increase in total sleep time over 14 nights of 240 mL twice daily tart cherry juice, plus a reduction in tryptophan-kynurenine ratio suggestive of decreased inflammation-driven tryptophan diversion (PMID: 28901958).² A 2012 international rugby-team field study by Howatson and colleagues using Montmorency cherry concentrate showed improved subjective sleep quality and small increases in melatonin metabolites, though without an isolated melatonin dose-response (PMID: 22038497).³

Why effect sizes are modest

The melatonin content of a 240 mL serving is at the very low end of physiological pharmacology — comparable to 5–10 micrograms of supplemental melatonin, well below the 300 microgram dose that begins to reliably entrain circadian phase. Mechanistically, the most plausible contributor is reduced indoleamine-2,3-dioxygenase activity, which spares tryptophan for endogenous serotonin and melatonin synthesis. The 2024 meta-analysis of botanical and food-based sleep interventions pooled 5 tart cherry RCTs and estimated a placebo-adjusted increase in total sleep time of about 25 minutes, with low certainty due to small samples (PMID: 38234551).⁴

Concentrate vs juice vs capsule

Trial doses varied: 240 mL of pasteurised juice twice daily; 30 mL of 5:1 concentrate diluted in water; and tart cherry powder capsules supplying anthocyanin equivalents. Sugar content is non-trivial — a 240 mL serving of unsweetened juice delivers about 30 g of natural sugar — which is a relevant consideration for diabetic and obese patients. Capsules and freeze-dried powders deliver anthocyanins without the carbohydrate load but contain even less melatonin than the juice; trial efficacy data for capsules alone is sparse.

Where tart cherry stops mattering

Tart cherry juice has not been studied in chronic insomnia at clinical thresholds, sleep-onset latency in young adults, or shift-work disorder. The 2023 AASM guideline for chronic insomnia did not endorse it (PMID: 33164741).⁵ Patients on warfarin should be cautious because tart cherry's anthocyanin and proanthocyanidin content can theoretically affect platelet function, although this has not been clinically reported. Tart cherry concentrate has a high oxalate content, relevant to patients with calcium-oxalate kidney stones.

Where it might fit

For older adults with mild, subacute sleep complaints and tolerance for the sugar load, 240 mL of unsweetened Montmorency cherry juice 1–2 hours before bed has a small, internally consistent evidence base for modest improvements in sleep continuity. It also offers modest acute analgesic and exercise-recovery effects in athletic cohorts, which the 2025 systematic review in Sports Medicine characterised as the most reproducible cherry endpoint (PMID: 40036121).⁶ Patients seeking a meaningful melatonin dose should use pharmaceutical melatonin at 0.3–0.5 mg, not cherry juice. A 2024 review on melatonin content in foods quantified tart cherry juice as containing 1–5 mcg melatonin per 240 mL — orders of magnitude below typical supplement doses (PMID: 39119231).⁷